<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="369">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01425944</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00038014</org_study_id>
    <secondary_id>U54NS065705-02</secondary_id>
    <secondary_id>BVMC6202</secondary_id>
    <nct_id>NCT01425944</nct_id>
  </id_info>
  <brief_title>Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome</brief_title>
  <official_title>The Brain Vascular Malformations Clinical Research Network: Predictors of Clinical Course, Project 2: Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has three aims that hope to expand the knowledge on the cause of Sturge-Weber
      Syndrome and improve clinical care of Sturge-Weber Syndrome patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is one of three projects of an NIH Rare Disease Clinical Research Consortium
      focused on brain blood vessel malformations in three different rare diseases.  The focus of
      this project is on Sturge-Weber Syndrome.

      We plan to improve the future understanding and treatment of Sturge-Weber Syndrome by 1)
      establishing a national consortium database which will gather lager amounts of clinical data
      and serve indirectly as a registry to foster future clinical trials, 2) determine the
      usefulness of urine vascular biomarkers, and 3) try to identify the hypothesized somatic
      mutation possibly causing SWS using DNA arrays.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Aim 1</measure>
    <time_frame>All 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Descriptive Statistics from National Database</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 2</measure>
    <time_frame>Years 1-3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between neuroscores and urine biomarkers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aim 3</measure>
    <time_frame>Years 1-4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Identification of candidate somatic mutation(s)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Sturge-Weber Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Aim 1 does not retain sample data. Aim 2 retains data without DNA. Aim 3 retains anonymous
      data with DNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        For Aim 1, population will be subjects with Sturge-Weber Syndrome and diagnosed brain
        involvement. For Aim 2, population will be subjects that have Sturge-Weber Syndrome with
        brain involvement, and a seperate group will be family members to have as a control. For
        Aim 3, population will be subjects with Sturge-Weber Syndrome, diagnosed brain
        involvement, and V1 distribution Port-Wine Stain.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For Aim 1:

          -  Sturge-Weber Syndrome

          -  Diagnosed Brain Involvement

        For Aim 2:

        For main sample:

          -  Sturge-Weber Syndrome

          -  Diagnosed Brain Involvement

        For Control:

          -  Family member of participating SWS patient

        For Aim 3:

          -  Sturge-Weber Syndrome

          -  Diagnosed Brain Involvement

          -  Port-Wine Stain in V1 and/or V2 areas of face.

        Exclusion Criteria:

          -  Not Diagnosed with Sturge-Weber Syndrome with Brain Involvement

        For Aim 2:

          -  Family member must not have certain medical conditions. A list will be provided
             before consent is given.

        For Aim 3:

          -  No Port-Wine Stain
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Comi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Bachur, B.A.</last_name>
    <phone>443.923.-9569</phone>
    <email>Bachur@kennedykrieger.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy D Bachur, B.A.</last_name>
      <phone>443-923-9569</phone>
      <email>bachur@kennedykrieger.org</email>
    </contact>
    <investigator>
      <last_name>Anne Comi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathie Germain</last_name>
      <phone>313-993-3848</phone>
      <email>cgermain@pet.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Csaba Juhasz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harry Chugani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren Lo, MD</last_name>
      <phone>617-722-4625</phone>
      <email>warren.lo@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Warren Lo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rizwan Alvi, MBBS</last_name>
      <phone>267-733-9697</phone>
      <email>ralvi@willseye.org</email>
    </contact>
    <investigator>
      <last_name>Alex Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Oroczo</last_name>
      <phone>832-822-1804</phone>
      <email>gxorozco@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Angus Wilfong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 31, 2013</lastchanged_date>
  <firstreceived_date>August 29, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</investigator_affiliation>
    <investigator_full_name>Anne Comi, MD</investigator_full_name>
    <investigator_title>Principal Investigator, Director Sturge-Weber Center, Kennedy Krieger Institute,Associate Professor Johns Hopkins University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sturge Weber Syndrome</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>DNA arrays</keyword>
  <keyword>brain vessel malformations</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
    <mesh_term>Sturge-Weber Syndrome</mesh_term>
    <mesh_term>Neurocutaneous Syndromes</mesh_term>
    <mesh_term>Brain Stem Infarctions</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
    <mesh_term>Central Nervous System Vascular Malformations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
